Market Cap 9.62B
Revenue (ttm) 829.45M
Net Income (ttm) -1.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -0.20%
Debt to Equity Ratio 0.51
Volume 1,555,300
Avg Vol 2,441,286
Day's Range N/A - N/A
Shares Out 135.81M
Stochastic %K 86%
Beta 1.28
Analysts Strong Sell
Price Target $59.25

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, t...

Industry: Biotechnology
Sector: Healthcare
Phone: 626 304 3400
Fax: 626 304 3401
Address:
177 East Colorado Boulevard, Suite 700, Pasadena, United States
ninergizer
ninergizer Dec. 13 at 2:33 AM
0 · Reply
LeftyT
LeftyT Dec. 12 at 9:16 PM
$SOXS and $SQQQ are both doing well as money continues to flow out of the inflated tech sector. Some of that cash is flowing back into $XBI biotech firms which are so far below fair value it's easy to pick rising star winners. Look at $ARWR, $ALT , ESPR, and ANVS for potential breakout news.
1 · Reply
Hello_kitty1
Hello_kitty1 Dec. 12 at 7:15 PM
$ARWR $ALNY, maybe just my imagination, but I feel someone is dumping ALNY for ARWR.
1 · Reply
Pantherfan7979
Pantherfan7979 Dec. 12 at 5:23 PM
1 · Reply
SBL71
SBL71 Dec. 12 at 1:48 PM
$ARWR ultimately, imo while not coming soon, but sooner hopefully with the FDA requirements on less trials than more, the obesity program ARO-ALK7 could be massive and the future of obesity personalized treatment. Way early but way cool.
1 · Reply
Quantumup
Quantumup Dec. 12 at 1:25 PM
Wedbush Added $WVE to it Best Idea List, while⬆️the PT to $33 and reiterating at an Outperform rating. $ARWR $RYTM LLY NVO VKTX AMGN GPCR GSK SRPT IONS SLDB PTCT Here's what Wedbush had to say in its note to investors: https://x.com/Quantumup1/status/1999469871310967131?s=20
0 · Reply
Quantumup
Quantumup Dec. 12 at 12:36 PM
Jefferies reiterated $WVE Buy-$26 $ARWR $RYTM $LLY NVO VKTX $AMGN GPCR Here's what Jefferies said: https://x.com/Quantumup1/status/1999457513343770753?s=20
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 12 at 8:31 AM
Enter: $ARWR Calls Strike Price: $75 Expiry Date: JAN 16 2026 Buy in Price: $4.10 - $4.70 Sell Price: $7.83 Profit : +91% (Turn every $1 into $1.91) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Oxdog
Oxdog Dec. 12 at 7:54 AM
$ARWR ARWR clearly rerated after the Nov 18 Redempto news — no debate there. Stock went from ~39 to ~69, about a 77% move. But since then we’ve had two much bigger developments that haven’t been properly priced in yet. First, the FDA discussion around reducing trial burden materially improves timelines and economics for RNAi. Second — and far more important — the CNS platform data. That fundamentally changes Arrowhead’s trajectory. This isn’t a single asset story anymore, it’s a validated CNS delivery platform. The market’s reaction so far feels like maybe 20% of what it should be, mostly because the data was delivered quietly to scientists, not hyped to retail, and analysts haven’t had time (or models) to absorb it yet. We are in a completely different space than Nov 17. The move from 39 to 69 was just the warm-up. The real rerate comes as the Street catches up and pharma interest turns into structure. The runway just got rocket fuel.
3 · Reply
Food4Thought
Food4Thought Dec. 12 at 7:07 AM
$ARWR Deep dive into some of the pipeline presented at 7th Annual CNS Delivery Summit ! Full presentation on link below. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://static.seekingalpha.com/uploads/sa_presentations/674/119674/original.pdf
0 · Reply
Latest News on ARWR
Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today

Nov 26, 2025, 7:16 PM EST - 16 days ago

Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today


Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Nov 25, 2025, 4:00 PM EST - 17 days ago

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results


US FDA approves Arrowhead's genetic disorder drug

Nov 18, 2025, 11:21 AM EST - 25 days ago

US FDA approves Arrowhead's genetic disorder drug


Privium Fund Management Sells Into Strength in Pharma Stock

Nov 4, 2025, 10:42 AM EST - 5 weeks ago

Privium Fund Management Sells Into Strength in Pharma Stock


Arrowhead (ARWR) Q3 Revenue Drops 41%

Aug 7, 2025, 5:37 PM EDT - 4 months ago

Arrowhead (ARWR) Q3 Revenue Drops 41%


Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Jun 4, 2025, 8:02 AM EDT - 6 months ago

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'


ninergizer
ninergizer Dec. 13 at 2:33 AM
0 · Reply
LeftyT
LeftyT Dec. 12 at 9:16 PM
$SOXS and $SQQQ are both doing well as money continues to flow out of the inflated tech sector. Some of that cash is flowing back into $XBI biotech firms which are so far below fair value it's easy to pick rising star winners. Look at $ARWR, $ALT , ESPR, and ANVS for potential breakout news.
1 · Reply
Hello_kitty1
Hello_kitty1 Dec. 12 at 7:15 PM
$ARWR $ALNY, maybe just my imagination, but I feel someone is dumping ALNY for ARWR.
1 · Reply
Pantherfan7979
Pantherfan7979 Dec. 12 at 5:23 PM
1 · Reply
SBL71
SBL71 Dec. 12 at 1:48 PM
$ARWR ultimately, imo while not coming soon, but sooner hopefully with the FDA requirements on less trials than more, the obesity program ARO-ALK7 could be massive and the future of obesity personalized treatment. Way early but way cool.
1 · Reply
Quantumup
Quantumup Dec. 12 at 1:25 PM
Wedbush Added $WVE to it Best Idea List, while⬆️the PT to $33 and reiterating at an Outperform rating. $ARWR $RYTM LLY NVO VKTX AMGN GPCR GSK SRPT IONS SLDB PTCT Here's what Wedbush had to say in its note to investors: https://x.com/Quantumup1/status/1999469871310967131?s=20
0 · Reply
Quantumup
Quantumup Dec. 12 at 12:36 PM
Jefferies reiterated $WVE Buy-$26 $ARWR $RYTM $LLY NVO VKTX $AMGN GPCR Here's what Jefferies said: https://x.com/Quantumup1/status/1999457513343770753?s=20
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 12 at 8:31 AM
Enter: $ARWR Calls Strike Price: $75 Expiry Date: JAN 16 2026 Buy in Price: $4.10 - $4.70 Sell Price: $7.83 Profit : +91% (Turn every $1 into $1.91) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Oxdog
Oxdog Dec. 12 at 7:54 AM
$ARWR ARWR clearly rerated after the Nov 18 Redempto news — no debate there. Stock went from ~39 to ~69, about a 77% move. But since then we’ve had two much bigger developments that haven’t been properly priced in yet. First, the FDA discussion around reducing trial burden materially improves timelines and economics for RNAi. Second — and far more important — the CNS platform data. That fundamentally changes Arrowhead’s trajectory. This isn’t a single asset story anymore, it’s a validated CNS delivery platform. The market’s reaction so far feels like maybe 20% of what it should be, mostly because the data was delivered quietly to scientists, not hyped to retail, and analysts haven’t had time (or models) to absorb it yet. We are in a completely different space than Nov 17. The move from 39 to 69 was just the warm-up. The real rerate comes as the Street catches up and pharma interest turns into structure. The runway just got rocket fuel.
3 · Reply
Food4Thought
Food4Thought Dec. 12 at 7:07 AM
$ARWR Deep dive into some of the pipeline presented at 7th Annual CNS Delivery Summit ! Full presentation on link below. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://static.seekingalpha.com/uploads/sa_presentations/674/119674/original.pdf
0 · Reply
Food4Thought
Food4Thought Dec. 12 at 6:59 AM
$ARWR Another price target increase. Quite a few now in the $80's. https://www.investing.com/news/analyst-ratings/arrowhead-pharma-stock-price-target-raised-to-80-from-52-at-rbc-capital-93CH-4402988
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:09 AM
Actionable Trade Alert for $ARWR: Market Context: $ARWR is currently trading at $70.61, showing a strong bullish momentum with an RSI of 82.64, indicating overbought conditions. The stock is significantly above its 30-day MA of 48.94 and 50-day MA of 44.33, suggesting a strong upward trend. Directional Bias: The high of $72.36 over the last 60 days indicates potential resistance, while the low of $29.81 establishes a solid support base. Given the current price proximity to the 60D high and the overbought RSI, caution is warranted, yet bullish sentiment remains. Trade Plan: - Suggested Entry: $70.61 - Stop Loss: $66.00 (approx. 6% below entry) - Take Profit Targets: 1. $73.00 (5.0% ROI) 2. $75.00 (6.8% ROI) 3. $82.50 (17% ROI) Monitor price action closely as it approaches targets, and adjust stop loss to lock in profits. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Stockinvestor77
Stockinvestor77 Dec. 12 at 12:04 AM
$ARWR in love with you arrowhead 😍
0 · Reply
FUDBusterzz
FUDBusterzz Dec. 11 at 10:18 PM
$ARWR I love you arrowhead
0 · Reply
FactsPlease99
FactsPlease99 Dec. 11 at 7:26 PM
$ARWR I like to buy strong stocks moving up...not falling knives. Bought first position $20 s, then $30 s, then $67.
0 · Reply
Metalscfo
Metalscfo Dec. 11 at 6:41 PM
$ARWR $SRPT 2026 should be a good year for $SRPT with DM1 read outs of $ARWR drug. 2025 is lost to tax lost harvesting. $SRPT will go no where until Jan 26.
0 · Reply
FactsPlease99
FactsPlease99 Dec. 11 at 5:47 PM
$ARWR $80 next stop ...added a few more this morning
0 · Reply
PaixTrader
PaixTrader Dec. 11 at 5:37 PM
$SRPT Anyone trying to read this refinancing as some negative signal for Elyvidis uptake is really reaching. Uptake has been improving since the labeling/regulatory update, and a simple debt restructuring like this just cleans up the balance sheet — what you’d expect from a company positioning itself for major catalysts (and potentially a future acquirer). $SRPT honestly should have never been put through the Elyvidis AMB drama. Prasad’s temp hold was an outrageous overreach and clearly hurt shareholders. Same with whatever forces cratered the stock price during that mess — mgmt was backed into a corner and even forced to sell ARWR shares under pressure. And the valuation disconnect is still insane. $SRPT remains massively undervalued vs $ARWR despite having a commercial franchise, maturing regulatory clarity, and real visibility into RNAi data. JPM will be the start of lifting this cloud, and early-2026 RNAi readouts should finally get SRPT valued closer to where ARWR trades.
4 · Reply
Stockinvestor77
Stockinvestor77 Dec. 11 at 4:09 PM
$ARWR we are holding new highs strong every single day 💪🏻
1 · Reply
WAJeff
WAJeff Dec. 11 at 3:31 PM
$ARWR $72.36 52 week high
0 · Reply
Steppinstone
Steppinstone Dec. 11 at 3:25 PM
$ARWR MAPT is another one where ARWR is in a great position. There are a couple of competitors with IONS/ Biogen and Denali. IONS/Biogen has the intra thecal administration of MAPT and an ASO and I just don’t see that one being very marketable. Denali is another ASO administered by IV infusion and not sure if it will have the efficacy of ARO-MAPT. The timing of ARWR getting outside of the liver with subq with its RNAi platform is really paying off now.
2 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 3:20 PM
RBC Capital has adjusted their stance on Arrowhead Pharma ( $ARWR ), setting the rating to Outperform with a target price of 52 → 80.
0 · Reply